Luyao Wang

Ovarian cancer is one of the main causes of death in women worldwide, despite new targeted therapies and immunotherapies, many patients with advanced-stage cancers still die, owing to metastatic disease. Adoptive T-cell therapy, involving the autologous or allogeneic transplant of tumour-infiltrating lymphocytes or genetically modified T cells expressing novel T-cell receptors or chimeric antigen receptors, has shown promise in the treatment of cancer patients. My ongoing work focuses on establishing a translation-ready therapeutic platform for treating ovarian cancer patients using adoptive T cell therapy.

I completed my Ph.D. with Professor Zhirong Zhang in the Pharmaceutics division of West China School of Pharmacy, Sichuan University. My Ph.D. project was about drug delivery systems and cancer therapy. During my Ph.D., I also have a one-year visiting study with prof. Walter Bodmer at the University of Oxford, doing research about colorectal cancer immunotherapy. From the drug delivery research for cancer to cancer immunotherapy and basic cancer biology exploration, this part of work really attracts me to continue. I am always passionate about cancer research, so I will continue the academic research in cancer biology and immunology with the goal to be an expert in this field and make some translations.